How long is the treatment course for platinib for lung cancer?

Pralsetinib (Pralsetinib), also known as BLU-667, is a potent and selective RET kinase inhibitor and has shown efficacy in tumors with oncogenic RET alterations. In vitro and in vivo models have shown that platinib can inhibit a wide range of RET changes, including KIF5B-RET, CCDC6-RET, and mutations encoding RET M918T, RET C634W, RET V804E, RET V804L, and RET V804M amino acid changes.

In theARROW study, 87 patients with RET fusion-positive non-small cell lung cancer who had previously received platinum-based chemotherapy received platinib 400 mg once daily (QD). At a median follow-up of 17.1 months, the overall response rate (ORR) was 61% (95% CI, 50-71), and the median progression-free survival (PFS) was 17.1 months (95% CI, 8.3-22.1) (interquartile range [IQR], 14.6-20.3). Among 27 treatment-naïve patients, the ORR was 19% (95% CI, 50-86), the median follow-up time was 11.6 months, and the median PFS was 9.1 months (IQR, 11.0-17.3).

The length of treatment may also be affected by the patient's overall health and side effects. If the patient tolerates platinib well and does not experience serious side effects, the treatment course may be relatively long. However, if a patient experiences severe side effects or is unable to tolerate the drug, the doctor may suspend or adjust the dose, or even consider discontinuing treatment. In addition, doctors will determine the course of treatment based on the patient's treatment goals. For some patients, the primary goals of treatment may be to relieve symptoms, improve quality of life, and extend survival; while for others, long-term control of the disease may be more focused.